Adjuvant Ipilimumab significantly effects recurrence-free survival in patients after resection of high risk lymph node positive melanoma
Results of an EORTC trial appearing in The Lancet Oncology [...]
EORTC organizing session on Cancer and Employment at European Business Summit 2015 in Brussels
European Business Summit, Europe's key meeting place for business leaders [...]
Webcasts of the EGAM 2015 plenary session are available for viewing
The plenary session presented information on the evolving structure of the [...]
Denis Lacombe succeeds Françoise Meunier as EORTC Director General
The EORTC is pleased to announce that Dr Denis Lacombe [...]
EORTC values ICO –VHIO as partners in its pan-European SPECTAcolor network
The EORTC has been very active assembling the pan-European [...]
14M Genomics and the EORTC collaborate on genomic profiling for clinical trials
Cambridge, UK: 10th March 2015. 14M Genomics (“14MG”) and the [...]
What does the future hold for treating patients with locally advanced breast cancer?
Treating patients with locally advanced inoperable breast cancer is an [...]
Improving treatment for patients with recurrent glioblastoma
EORTC 1410-BTG/AbbVie M14-483 The median survival for patients diagnosed with [...]
EORTC opens trial for patients with high grade undifferentiated uterine sarcoma, a rare cancer
Uterine sarcomas account for just 1% of female genital tract [...]
Saskia Litière, Biostatistician at the EORTC, discusses the ongoing evaluation of RECIST with Helen Saul
Hear Saskia Litière, EORTC Biostatistician, discuss "The components of progression [...]
